Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trial

Jeffrey R. Curtis, Theresa McVie, Ted R Mikuls, Richard J. Reynolds, Iris Navarro-Millań, James Robert O'Dell, Larry W. Moreland, S. Louis Bridges, Veena K. Ranganath, Stacey S. Cofield

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective. Rapidly predicting future outcomes based on short-term clinical response would be helpful to optimize rheumatoid arthritis (RA) management in early disease. Our aim was to derive and validate a clinical prediction rule to predict low disease activity (LDA) at 1 year among patients participating in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial escalating RA therapy by adding either etanercept or sulfasalazine + hydroxychloroquine [triple therapy (TT)] after 6 months of methotrexate (MTX) therapy. Methods. Eligible subjects included in the derivation cohort (used for model building, n = 186) were participants with moderate or higher disease activity [Disease Activity Score 28-erythrocyte sedimentation rate (DAS-ESR) > 3.2] despite 24 weeks of MTX monotherapy who added either etanercept or sulfasalazine + hydroxychloroquine. Clinical characteristics measured within the next 12 weeks were used to predict LDA 1 year later using multivariable logistic regression. Validation was performed in the cohort of TEAR patients randomized to initially receive either MTX + etanercept or TT. Results. The derivation cohort yielded 3 prediction models of varying complexity that included age, DAS28 at various timepoints, body mass index, and ESR (area under the receiver-operator characteristic curve up to 0.83). Accuracy of the prediction models ranged between 80% and 95% in both derivation and validation cohorts, depending on the complexity of the model and the cutpoints chosen for response and nonresponse. About 80% of patients could be predicted to be responders or nonresponders at Week 12. Conclusion. Clinical data collected early after starting or escalating disease-modifying antirheumatic drug/biologic treatment could accurately predict LDA at 1 year in patients with early RA. For patients predicted to be nonresponders, treatment could be changed at 12 weeks to optimize outcomes. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)572-578
Number of pages7
JournalJournal of Rheumatology
Volume40
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Rheumatoid Arthritis
Methotrexate
Hydroxychloroquine
Sulfasalazine
Therapeutics
Antirheumatic Agents
Decision Support Techniques
Blood Sedimentation
Rheumatology
Biological Products
Body Mass Index
Logistic Models
Etanercept

Keywords

  • ETANERCEPT
  • PREDICTION
  • RHEUMATOID ARTHRITIS
  • TRIPLE THERAPY
  • TUMOR NECROSIS FACTOR INHIBITOR

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA : Results from the TEAR trial. / Curtis, Jeffrey R.; McVie, Theresa; Mikuls, Ted R; Reynolds, Richard J.; Navarro-Millań, Iris; O'Dell, James Robert; Moreland, Larry W.; Bridges, S. Louis; Ranganath, Veena K.; Cofield, Stacey S.

In: Journal of Rheumatology, Vol. 40, No. 5, 01.05.2013, p. 572-578.

Research output: Contribution to journalArticle

Curtis, JR, McVie, T, Mikuls, TR, Reynolds, RJ, Navarro-Millań, I, O'Dell, JR, Moreland, LW, Bridges, SL, Ranganath, VK & Cofield, SS 2013, 'Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trial', Journal of Rheumatology, vol. 40, no. 5, pp. 572-578. https://doi.org/10.3899/jrheum.120715
Curtis, Jeffrey R. ; McVie, Theresa ; Mikuls, Ted R ; Reynolds, Richard J. ; Navarro-Millań, Iris ; O'Dell, James Robert ; Moreland, Larry W. ; Bridges, S. Louis ; Ranganath, Veena K. ; Cofield, Stacey S. / Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA : Results from the TEAR trial. In: Journal of Rheumatology. 2013 ; Vol. 40, No. 5. pp. 572-578.
@article{f8153bb37efc4678a1bc54ef90f1fe0a,
title = "Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trial",
abstract = "Objective. Rapidly predicting future outcomes based on short-term clinical response would be helpful to optimize rheumatoid arthritis (RA) management in early disease. Our aim was to derive and validate a clinical prediction rule to predict low disease activity (LDA) at 1 year among patients participating in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial escalating RA therapy by adding either etanercept or sulfasalazine + hydroxychloroquine [triple therapy (TT)] after 6 months of methotrexate (MTX) therapy. Methods. Eligible subjects included in the derivation cohort (used for model building, n = 186) were participants with moderate or higher disease activity [Disease Activity Score 28-erythrocyte sedimentation rate (DAS-ESR) > 3.2] despite 24 weeks of MTX monotherapy who added either etanercept or sulfasalazine + hydroxychloroquine. Clinical characteristics measured within the next 12 weeks were used to predict LDA 1 year later using multivariable logistic regression. Validation was performed in the cohort of TEAR patients randomized to initially receive either MTX + etanercept or TT. Results. The derivation cohort yielded 3 prediction models of varying complexity that included age, DAS28 at various timepoints, body mass index, and ESR (area under the receiver-operator characteristic curve up to 0.83). Accuracy of the prediction models ranged between 80{\%} and 95{\%} in both derivation and validation cohorts, depending on the complexity of the model and the cutpoints chosen for response and nonresponse. About 80{\%} of patients could be predicted to be responders or nonresponders at Week 12. Conclusion. Clinical data collected early after starting or escalating disease-modifying antirheumatic drug/biologic treatment could accurately predict LDA at 1 year in patients with early RA. For patients predicted to be nonresponders, treatment could be changed at 12 weeks to optimize outcomes. The Journal of Rheumatology",
keywords = "ETANERCEPT, PREDICTION, RHEUMATOID ARTHRITIS, TRIPLE THERAPY, TUMOR NECROSIS FACTOR INHIBITOR",
author = "Curtis, {Jeffrey R.} and Theresa McVie and Mikuls, {Ted R} and Reynolds, {Richard J.} and Iris Navarro-Millań and O'Dell, {James Robert} and Moreland, {Larry W.} and Bridges, {S. Louis} and Ranganath, {Veena K.} and Cofield, {Stacey S.}",
year = "2013",
month = "5",
day = "1",
doi = "10.3899/jrheum.120715",
language = "English (US)",
volume = "40",
pages = "572--578",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA

T2 - Results from the TEAR trial

AU - Curtis, Jeffrey R.

AU - McVie, Theresa

AU - Mikuls, Ted R

AU - Reynolds, Richard J.

AU - Navarro-Millań, Iris

AU - O'Dell, James Robert

AU - Moreland, Larry W.

AU - Bridges, S. Louis

AU - Ranganath, Veena K.

AU - Cofield, Stacey S.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Objective. Rapidly predicting future outcomes based on short-term clinical response would be helpful to optimize rheumatoid arthritis (RA) management in early disease. Our aim was to derive and validate a clinical prediction rule to predict low disease activity (LDA) at 1 year among patients participating in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial escalating RA therapy by adding either etanercept or sulfasalazine + hydroxychloroquine [triple therapy (TT)] after 6 months of methotrexate (MTX) therapy. Methods. Eligible subjects included in the derivation cohort (used for model building, n = 186) were participants with moderate or higher disease activity [Disease Activity Score 28-erythrocyte sedimentation rate (DAS-ESR) > 3.2] despite 24 weeks of MTX monotherapy who added either etanercept or sulfasalazine + hydroxychloroquine. Clinical characteristics measured within the next 12 weeks were used to predict LDA 1 year later using multivariable logistic regression. Validation was performed in the cohort of TEAR patients randomized to initially receive either MTX + etanercept or TT. Results. The derivation cohort yielded 3 prediction models of varying complexity that included age, DAS28 at various timepoints, body mass index, and ESR (area under the receiver-operator characteristic curve up to 0.83). Accuracy of the prediction models ranged between 80% and 95% in both derivation and validation cohorts, depending on the complexity of the model and the cutpoints chosen for response and nonresponse. About 80% of patients could be predicted to be responders or nonresponders at Week 12. Conclusion. Clinical data collected early after starting or escalating disease-modifying antirheumatic drug/biologic treatment could accurately predict LDA at 1 year in patients with early RA. For patients predicted to be nonresponders, treatment could be changed at 12 weeks to optimize outcomes. The Journal of Rheumatology

AB - Objective. Rapidly predicting future outcomes based on short-term clinical response would be helpful to optimize rheumatoid arthritis (RA) management in early disease. Our aim was to derive and validate a clinical prediction rule to predict low disease activity (LDA) at 1 year among patients participating in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial escalating RA therapy by adding either etanercept or sulfasalazine + hydroxychloroquine [triple therapy (TT)] after 6 months of methotrexate (MTX) therapy. Methods. Eligible subjects included in the derivation cohort (used for model building, n = 186) were participants with moderate or higher disease activity [Disease Activity Score 28-erythrocyte sedimentation rate (DAS-ESR) > 3.2] despite 24 weeks of MTX monotherapy who added either etanercept or sulfasalazine + hydroxychloroquine. Clinical characteristics measured within the next 12 weeks were used to predict LDA 1 year later using multivariable logistic regression. Validation was performed in the cohort of TEAR patients randomized to initially receive either MTX + etanercept or TT. Results. The derivation cohort yielded 3 prediction models of varying complexity that included age, DAS28 at various timepoints, body mass index, and ESR (area under the receiver-operator characteristic curve up to 0.83). Accuracy of the prediction models ranged between 80% and 95% in both derivation and validation cohorts, depending on the complexity of the model and the cutpoints chosen for response and nonresponse. About 80% of patients could be predicted to be responders or nonresponders at Week 12. Conclusion. Clinical data collected early after starting or escalating disease-modifying antirheumatic drug/biologic treatment could accurately predict LDA at 1 year in patients with early RA. For patients predicted to be nonresponders, treatment could be changed at 12 weeks to optimize outcomes. The Journal of Rheumatology

KW - ETANERCEPT

KW - PREDICTION

KW - RHEUMATOID ARTHRITIS

KW - TRIPLE THERAPY

KW - TUMOR NECROSIS FACTOR INHIBITOR

UR - http://www.scopus.com/inward/record.url?scp=84876925323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876925323&partnerID=8YFLogxK

U2 - 10.3899/jrheum.120715

DO - 10.3899/jrheum.120715

M3 - Article

C2 - 23588939

AN - SCOPUS:84876925323

VL - 40

SP - 572

EP - 578

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -